Zantac Eligibility Requirements

Requirement 1: Duration and Consistency of Ranitidine Use

Most Zantac plaintiff's law firms require a minimum of one year of consistent use of Zantac (ranitidine) or generic ranitidine to establish meaningful cumulative NDMA exposure. This threshold reflects the pharmacokinetic and epidemiological evidence showing that cancer risk from NDMA is a function of sustained, repeated exposure over time — not acute or occasional use. Both prescription ranitidine and over-the-counter Zantac qualify. Use does not need to have been daily or uninterrupted; patients who used ranitidine several times per week for chronic heartburn or GERD management over a multi-year period can satisfy the use requirement. The important factors are the total duration of the use period and the frequency of use within that period. Use prior to the April 2020 FDA withdrawal is most relevant, as that is when ranitidine products were available for purchase. Evidence of use includes pharmacy prescription records, insurance claims data, store loyalty card purchase histories, and corroborating physician records documenting ranitidine prescriptions or OTC use discussions.

Requirement 2: Qualifying Cancer Diagnosis

You must have been diagnosed with a cancer type that is accepted in active Zantac state court litigation. The most widely accepted qualifying cancers are: bladder cancer (urothelial carcinoma), stomach (gastric) cancer, colorectal cancer (colon and rectal), and esophageal cancer. Breast cancer and prostate cancer are also pursued as qualifying diagnoses by many plaintiff's firms. The cancer diagnosis must be confirmed by pathology report. Any stage qualifies, though earlier-stage diagnoses result in lower settlement values than advanced-stage or metastatic disease. A cancer diagnosis that predates any significant period of ranitidine use (i.e., you had cancer before you started taking Zantac) would not qualify.

Requirement 3: Medically Plausible Exposure-to-Diagnosis Timeline

There must be a medically plausible latency period between the period of ranitidine use and the cancer diagnosis. Cancer induced by chemical carcinogens such as NDMA typically develops over years to decades — short-term exposure immediately before diagnosis would not support a causal theory. Claimants who used ranitidine for several years and were diagnosed with a qualifying cancer several years or more after beginning use present the strongest timeline. For example, a patient who used ranitidine from 2005 to 2018 and was diagnosed with bladder cancer in 2021 has a compelling timeline — the diagnosis follows years of cumulative NDMA exposure with adequate latency. Conversely, a patient who began using ranitidine in January 2020 and was diagnosed with cancer in June 2020 would face serious timeline challenges.

Requirement 4: Filing Within the Statute of Limitations

Your claim must be timely under the applicable state statute of limitations. In pharmaceutical cases, the discovery rule typically governs — the clock begins when you knew or should have known that Zantac may have caused your cancer. The April 2020 FDA market withdrawal is often cited as the date when public notice of the NDMA-ranitidine connection became widely available, meaning that in many states the limitations period began running in April 2020. Claimants diagnosed with qualifying cancers in 2022 or later, or those who can demonstrate delayed discovery of the Zantac connection, may still have timely claims in 2026. A pharmaceutical litigation attorney can evaluate the specific limitations period applicable to your diagnosis date and state.